Contact
Please use this form to send email to PR contact of this press release:
Human medicines European public assessment report (EPAR): Enhertu, trastuzumab deruxtecan, Breast Neoplasms, Date of authorisation: 18/01/2021, Revision: 11, Status: Authorised
TO: